Literature DB >> 8605467

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management in adults.

.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8605467      PMCID： PMC2350463          DOI： 10.1136/bmj.312.7033.762

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  66 in total

1.  North of England evidence based guidelines development project: methods of guideline development.

Authors:  M Eccles; Z Clapp; J Grimshaw; P C Adams; B Higgins; I Purves; I Russell
Journal:  BMJ       Date:  1996-03-23

2.  A group comparative study of the safety and efficacy of nedocromil sodium (Tilade) in reversible airways disease: a preliminary report.

Authors:  A van As; T W Chick; S F Bodman; W W Storms; R A Nathan; J C Selner; J W Koepke; R G Townley; A K Bewtra; N Nair
Journal:  Eur J Respir Dis Suppl       Date:  1986

3.  A multicentre double-blind group comparative trial of two dose levels of nedocromil sodium and placebo in the management of perennial extrinsic asthma.

Authors:  D B Greco; E B Negreiros; J A Chaieb; P Ferreira-Lima; J Croce
Journal:  Eur J Respir Dis Suppl       Date:  1986

4.  A double-blind comparative trial of nedocromil sodium and placebo in the management of bronchial asthma in patients routinely using oral bronchodilators.

Authors:  F Cua-Lim; B F Agbayani; D Lachica
Journal:  Eur J Respir Dis Suppl       Date:  1986

5.  Controlled evaluation of the effects of patient education on asthma morbidity in general practice.

Authors:  S Hilton; B Sibbald; H R Anderson; P Freeling
Journal:  Lancet       Date:  1986-01-04       Impact factor: 79.321

6.  Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma.

Authors:  M Gagnon; J Côte; J Milot; H Turcotte; L P Boulet
Journal:  Chest       Date:  1994-06       Impact factor: 9.410

7.  Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy.

Authors:  B Billing; R Dahlqvist; Y Hörnblad; T Leideman; L Skareke; E Ripe
Journal:  Eur J Respir Dis       Date:  1987-01

8.  High-dose inhaled budesonide in treatment of severe steroid-dependent asthma.

Authors:  L C Laursen; E Taudorf; B Weeke
Journal:  Eur J Respir Dis       Date:  1986-01

9.  Regular vs as-needed inhaled salbutamol in asthma control.

Authors:  K R Chapman; S Kesten; J P Szalai
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

10.  Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study.

Authors:  S Salmeron; L Brochard; H Mal; A Tenaillon; M Henry-Amar; D Renon; P Duroux; G Simonneau
Journal:  Am J Respir Crit Care Med       Date:  1994-06       Impact factor: 21.405
View more
  6 in total

1.  Updating guidelines on asthma in adults.

Authors:  B Delaney
Journal:  BMJ       Date:  2001-12-15

2.  Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community.

Authors:  Carol Armour; Sinthia Bosnic-Anticevich; Martha Brillant; Debbie Burton; Lynne Emmerton; Ines Krass; Bandana Saini; Lorraine Smith; Kay Stewart
Journal:  Thorax       Date:  2007-01-24       Impact factor: 9.139

3.  A 10 year asthma programme in Finland: major change for the better.

Authors:  T Haahtela; L E Tuomisto; A Pietinalho; T Klaukka; M Erhola; M Kaila; M M Nieminen; E Kontula; L A Laitinen
Journal:  Thorax       Date:  2006-08       Impact factor: 9.139

4.  Chronic obstructive pulmonary disease. No longer any justification for therapeutic nihilism.

Authors:  D R Taylor
Journal:  BMJ       Date:  1998-05-16

5.  North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care.

Authors:  M Eccles; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-04-18

Review 6.  Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.

Authors:  R A Bartow; R N Brogden
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.